|
1.
|
Clemens JQ, Link CL, Eggers PW, Kusek JW,
Nyberg LM and McKinlay JB: BACH Survey Investigators: Prevalence of
painful bladder symptoms and effect on quality of life in black,
Hispanic and white men and women. J Urol. 177:1390–1394. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Held PJ, Hanno PM, Wein AJ, Pauly MV and
Cahn MA: Epidemiology of interstitial cystitis. Interstitial
Cystitis. Hanno PM, Staskin DR, Krane RJ and Wein AJ: (London).
Springer. 29–48. 1990. View Article : Google Scholar
|
|
3.
|
Gillenwater JY and Wein AJ: Summary of the
National Institute of Arthritis, Diabetes, Digestive and Kidney
Diseases workshop on interstitial cystitis, National Institutes of
Health, Bethesda, Maryland, August 28–29, 1987. J Urol.
140:203–206. 1988.PubMed/NCBI
|
|
4.
|
Ogawa H, Kameda H, Amano K and Takeuchi T:
Efficacy and safety of cyclosporine A in patients with refractory
systemic lupus erythematosus in a daily clinical practice. Lupus.
19:162–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Forns X and Navasa M: Cyclosporine A or
tacrolimus for hepatitis C recurrence? An old debate. Am J
Transplant. 11:1559–1560. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Maza A, Montaudiè H, Sbidian E, Gallini A,
Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, et
al: Oral cyclosporin in psoriasis: A systematic review on treatment
modalities, risk of kidney toxicity and evidence for use in
non-plaque psoriasis. J Eur Acad Dermatol Venereol. 25(Suppl 2):
S19–S27. 2011. View Article : Google Scholar
|
|
7.
|
Sternthal MB, Murphy SJ, George J,
Kornbluth A, Lichtiger S and Present DH: Adverse events associated
with the use of cyclosporine in patients with inflammatory bowel
disease. Am J Gastroenterol. 103:937–943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Dijkmans B and Gerards A: Cyclosporin in
rheumatoid arthritis: Monitoring for adverse effects and clinically
significant drug interactions. BioDrugs. 10:437–445. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analysis. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Jadad AR, Moore RA, Carroll D, Jenkinson
C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ehrén I, Grufman Hallén K, Vrba M,
Sundelin R and Lafolie P: Nitric oxide as a marker for evaluation
of treatment effect of cyclosporine A in patients with bladder pain
syndrome/interstitial cystitis type 3C. Scand J Urol. 47:503–508.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chade J, Chade D, Lucon AM, Bruschini H
and Srougi M: 462 5-year follow-up of patients with refractory
interstitial cystitis treated with cyclosporine A: A prospective
single-institution study. Eur Urol. (Supp 13): e4622014. View Article : Google Scholar
|
|
13.
|
Forrest JB, Payne CK and Erickson DR:
Cyclosporine A for refractory interstitial cystitis/bladder pain
syndrome: Experience of 3 tertiary centers. J Urol. 188:1186–1191.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Sairanen J, Forsell T and Ruutu M:
Long-term outcome of patients with interstitial cystitis treated
with low dose cyclosporine A. J Urol. 171:2138–2141. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Forsell T, Ruutu M, Isoniemi H, Ahonen J
and Alfthan O: Cyclosporine in severe interstitial cystitis. J
Urol. 155:1591–1593. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sairanen J, Tammela TL, Leppilahti M,
Multanen M, Paananen I, Lehtoranta K and Ruutu M: Cyclosporine A
and pentosan polysulfate sodium for the treatment of interstitial
cystitis: A randomized comparative study. J Urol. 174:2235–2238.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sairanen J, Hotakainen K, Tammela TL,
Stenman UH and Ruutu M: Urinary epidermal growth factor and
interleukin-6 levels in patients with painful bladder
syndrome/interstitial cystitis treated with cyclosporine or
pentosan polysulfate sodium. Urology. 71:630–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sairanen J, Tammela TL, Leppilahti M,
Onali M, Forsell T and Ruutu M: Potassium sensitivity test (PST) as
a measurement of treatment efficacy of painful bladder
syndrome/interstitial cystitis: A prospective study with
cyclosporine A and pentosan polysulfate sodium. Neurourol Urodyn.
26:267–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gao X, Ma Y, Sun L, Chen D, Mei C and Xu
C: Cyclosporine A for the treatment of refractory nephritic
syndrome with renal dysfunction. Exp Ther Med. 7:447–450.
2014.PubMed/NCBI
|
